RESUMO
Acute stress disorder and post-traumatic stress disorder are generally triggered by an exceptionally intense threat. The consequences of this traumatogenic situation are explored here in chronological order, from exposure to the threat to development of symptoms. Such a situation may disrupt the equilibrium between two fundamental brain circuits, referred to as the "defensive" and "cognitive". The defensive circuit triggers the stress response as well as the formation of implicit memory. The cognitive circuit triggers the voluntary response and the formation of explicit autobiographical memory. During a traumatogenic situation, the defensive circuit could be over-activated while cognitive circuit is under-activated. In the most severe cases, overactivation of the defensive circuit may cause its brutal deactivation, resulting in dissociation. Here, we address the underlying neurobiological mechanisms at every scale: from neurons to behaviors, providing a detailed explanatory model of trauma.
Assuntos
Transtornos de Estresse Pós-Traumáticos , Humanos , Memória Episódica , Sistema NervosoAssuntos
Antipsicóticos/uso terapêutico , Betacoronavirus , Clozapina/uso terapêutico , Infecções por Coronavirus/complicações , Fatores Imunológicos/uso terapêutico , Palmitato de Paliperidona/uso terapêutico , Pandemias , Pneumonia Viral/complicações , Transtornos Psicóticos/tratamento farmacológico , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/uso terapêutico , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , COVID-19 , Clozapina/administração & dosagem , Clozapina/efeitos adversos , Preparações de Ação Retardada , Resistência a Medicamentos , Quimioterapia Combinada , Humanos , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/efeitos adversos , Carbonato de Lítio/administração & dosagem , Carbonato de Lítio/uso terapêutico , Masculino , Pessoa de Meia-Idade , Palmitato de Paliperidona/administração & dosagem , SARS-CoV-2 , Sialorreia/induzido quimicamente , Resultado do Tratamento , Ácido Valproico/administração & dosagem , Ácido Valproico/uso terapêuticoRESUMO
BACKGROUND: The Paris and Nice terrorist attacks affected a thousand of trauma victims and first-line responders. Because there were concerns that this might represent the first of several attacks, there was a need to quickly enhance the local capacities to treat a large number of individuals suffering from trauma-related disorders. Since Reconsolidation Therapy (RT) is brief, relatively easy to learn, well tolerated and effective, it appeared as the ideal first-line treatment to teach to clinicians in this context. METHODS: This study protocol is a two-arm non-randomized, multicenter controlled trial, comparing RT to treatment as usual for the treatment of trauma-related disorders. RT consists of actively recalling one's traumatic event under the influence of the ß-blocker propranolol, once a week, for 10-25 min with a therapist, over 6 consecutive weeks. This protocol evaluates the feasibility, effectiveness, and cost-utility of implementing RT as part of a large multi-center (N = 400) pragmatic trial with a one-year follow-up. DISCUSSION: Paris MEM is the largest trial to date assessing the efficiency of RT in the aftermath of a large-scale man-made disaster. RT could possibly reinforce the therapeutic arsenal for the treatment of patients suffering from trauma-related disorders, not only for communities in western countries but also worldwide for terror- or disaster-stricken communities. TRIAL REGISTRATION: Clinical Trials (ClinicalTrials.gov). June 3, 2016. NCT02789982.
Assuntos
Terapia Cognitivo-Comportamental/métodos , Transtornos de Estresse Pós-Traumáticos/terapia , Terrorismo/psicologia , Adulto , Feminino , França , História do Século XXI , Humanos , Masculino , Consolidação da Memória , Transtornos de Estresse Pós-Traumáticos/etiologia , Terrorismo/história , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Schizophrenia is a disabling disease with a significant proportion of patients experiencing persistent symptoms. Repetitive transcranial magnetic stimulation (rTMS) is a promising new therapeutic tool that could benefit to schizophrenic patients. In this study we sought to assess the efficacy of active rTMS compared to sham stimulation in the treatment of patients with schizophrenia. METHOD: Eighteen schizophrenic patients according to DSM-IV criteria were randomly allocated to receive active or sham rTMS for 10 days over the left temporoparietal cortex (80% of the motor threshold, 1Hz, five trains of 1 min). Psychopathological dimensions were measured with the positive and negative syndrome scale and clinical global impression at baseline and after 10 session of rTMS. RESULTS: All patients were improved at the end of the trial but no significant group differences were found. Patients receiving sham stimulation showed the same pattern of improvement compared to active condition on all the subscales of the positive and negative syndrome scale and clinical global impression scores (p>0.05). CONCLUSION: In our study, active rTMS failed to show superiority over sham stimulation in the treatment of schizophrenic symptoms. Although previous results have shown that rTMS reduces auditory hallucination, its efficacy on other positive schizophrenic symptoms is not yet established. Nevertheless, the results of our study, even though negative, provide further insights in the pathophysiology of schizophrenia.